Benzinga
Benzinga
Benzinga
mercredi, septembre 23

Viridian Therapeutics Inc

VRDNNASDAQ
Trade with Public
Trade with Public
$22.12
0.542.5%
À la clôture: Sep 21, 5:00 PM EST
$22.24
0.663.06%
Pré-ouverture: 8:31 AM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Viridian Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Viridian Therapeutics (VRDN).

Price Target Range — 12 Quarters

Analyst Consensus — 17 Analysts

1S.Buy
14Buy
2Hold
Consensus RatingBuy# Analysts17Avg. Consensus PT$37Upside to Avg. PT+68.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →
DateFirmAnalystActionRating ChangePrice Target
Sep 22, 2026RBC CapitalLisa WalterPT RaiseOutperform$36→$38
Aug 7, 2026RBC CapitalLisa WalterPT RaiseOutperform$35→$36
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $36 to $38.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $35 to $36.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $38 to $39.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $34 to $35.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $35 to $38.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43

Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $32 to $43.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved